Efficacy of immune checkpoint inhibitors combined with bevacizumab in MSS/pMMR advanced colorectal cancer after first-line treatment failure
By administering immune checkpoint inhibitors in combination with bevacizumab to patients with advanced colorectal cancer with MSS/pMMR disease for whom first-line treatment failed, not only did the patients' prognosis improve, but the adverse drug reactions were also safe and controllable.
Authors
- Xinfu Ma
- Zhanhong Li (ORCID: https://orcid.org/0000-0002-3552-7545)
- Xiaoqian Chen (ORCID: https://orcid.org/0000-0001-9255-3371)
- Yushuang Luo (ORCID: https://orcid.org/0000-0003-3239-7260)
- Wenkui Li (ORCID: https://orcid.org/0000-0002-1739-9957)
- Xiaogai Lei
- Qijing Guo
- Liang Wang (ORCID: https://orcid.org/0000-0001-5224-8647)
Institutions
- Qinghai University Affiliated Hospital (CN)
- Qinghai No.3 People's Hospital (CN)
- Qinghai Red Cross Hospital (CN)
- Xian Yang Central Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-08-12
- DOI
- https://doi.org/10.3389/fonc.2024.1429095
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.57